• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DNA微阵列研究的效能与样本量

Power and sample size for DNA microarray studies.

作者信息

Lee Mei-Ling Ting, Whitmore G A

机构信息

Department of Medicine, Brigham and Women's Hospital, Boston, USA.

出版信息

Stat Med. 2002 Dec 15;21(23):3543-70. doi: 10.1002/sim.1335.

DOI:10.1002/sim.1335
PMID:12436455
Abstract

A microarray study aims at having a high probability of declaring genes to be differentially expressed if they are truly expressed, while keeping the probability of making false declarations of expression acceptably low. Thus, in formal terms, well-designed microarray studies will have high power while controlling type I error risk. Achieving this objective is the purpose of this paper. Here, we discuss conceptual issues and present computational methods for statistical power and sample size in microarray studies, taking account of the multiple testing that is generic to these studies. The discussion encompasses choices of experimental design and replication for a study. Practical examples are used to demonstrate the methods. The examples show forcefully that replication of a microarray experiment can yield large increases in statistical power. The paper refers to cDNA arrays in the discussion and illustrations but the proposed methodology is equally applicable to expression data from oligonucleotide arrays.

摘要

微阵列研究的目标是,如果基因确实存在差异表达,那么就有很高的概率宣称这些基因存在差异表达,同时将做出错误表达宣称的概率控制在可接受的低水平。因此,从形式上来说,设计良好的微阵列研究在控制I型错误风险的同时将具有高功效。实现这一目标就是本文的目的。在这里,我们讨论概念性问题,并给出微阵列研究中统计功效和样本量的计算方法,同时考虑到这些研究中普遍存在的多重检验。讨论内容包括研究的实验设计和重复的选择。通过实际例子来演示这些方法。这些例子有力地表明,微阵列实验的重复可以显著提高统计功效。本文在讨论和举例时提及了cDNA阵列,但所提出的方法同样适用于来自寡核苷酸阵列的表达数据。

相似文献

1
Power and sample size for DNA microarray studies.DNA微阵列研究的效能与样本量
Stat Med. 2002 Dec 15;21(23):3543-70. doi: 10.1002/sim.1335.
2
Split-plot microarray experiments: issues of design, power and sample size.裂区微阵列实验:设计、功效和样本量问题
Appl Bioinformatics. 2005;4(3):187-94. doi: 10.2165/00822942-200504030-00003.
3
Sample size for detecting differentially expressed genes in microarray experiments.用于检测微阵列实验中差异表达基因的样本量。
BMC Genomics. 2004 Nov 8;5:87. doi: 10.1186/1471-2164-5-87.
4
Identifying differentially expressed genes using false discovery rate controlling procedures.使用错误发现率控制程序识别差异表达基因。
Bioinformatics. 2003 Feb 12;19(3):368-75. doi: 10.1093/bioinformatics/btf877.
5
Estimating effect sizes of differentially expressed genes for power and sample-size assessments in microarray experiments.在微阵列实验中估计差异表达基因的效应大小以进行功效和样本量评估。
Biometrics. 2011 Dec;67(4):1225-35. doi: 10.1111/j.1541-0420.2011.01618.x. Epub 2011 May 31.
6
An evaluation of statistical methods for DNA methylation microarray data analysis.DNA甲基化微阵列数据分析统计方法的评估
BMC Bioinformatics. 2015 Jul 10;16:217. doi: 10.1186/s12859-015-0641-x.
7
Replication, variation and normalisation in microarray experiments.微阵列实验中的复制、变异与标准化
Appl Bioinformatics. 2005;4(1):33-44. doi: 10.2165/00822942-200504010-00004.
8
Microarray experimental design: power and sample size considerations.微阵列实验设计:效能与样本量考量
Physiol Genomics. 2003 Dec 16;16(1):24-8. doi: 10.1152/physiolgenomics.00037.2003.
9
False discovery rate, sensitivity and sample size for microarray studies.微阵列研究的错误发现率、敏感性和样本量
Bioinformatics. 2005 Jul 1;21(13):3017-24. doi: 10.1093/bioinformatics/bti448. Epub 2005 Apr 19.
10
Sample size for identifying differentially expressed genes in microarray experiments.微阵列实验中用于鉴定差异表达基因的样本量。
J Comput Biol. 2004;11(4):714-26. doi: 10.1089/cmb.2004.11.714.

引用本文的文献

1
Profiles of urinal exosomal miRNAs derived from bladder cancer.源自膀胱癌的尿外泌体微小RNA概况
Cent European J Urol. 2024;77(3):361-374. doi: 10.5173/ceju.2023.279.R1. Epub 2024 Sep 30.
2
Computing Power and Sample Size for the False Discovery Rate in Multiple Applications.多应用中的错误发现率的计算能力和样本量。
Genes (Basel). 2024 Mar 7;15(3):344. doi: 10.3390/genes15030344.
3
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma.
广泛的血浆蛋白质组学分析显示,核因子κB 受体激活物配体(RANKL)是转移性肾细胞癌患者纳武利尤单抗临床获益的新兴生物标志物。
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005136.
4
Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients.细胞外囊泡的大规模分析确定miR-625-5p为晚期非小细胞肺癌患者免疫治疗反应的新型生物标志物。
Cancers (Basel). 2022 May 14;14(10):2435. doi: 10.3390/cancers14102435.
5
Pig Genomics and Genetics.猪的基因组学与遗传学。
Genes (Basel). 2021 Oct 25;12(11):1692. doi: 10.3390/genes12111692.
6
RNASeqDesign: A framework for RNA-Seq genome-wide power calculation and study design issues.RNA序列设计:一种用于全基因组RNA序列功效计算及研究设计问题的框架。
J R Stat Soc Ser C Appl Stat. 2019 Apr;68(3):683-704. doi: 10.1111/rssc.12330. Epub 2018 Dec 9.
7
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells.血液转录组学预测肺纤维化的进展及相关自然杀伤细胞。
Am J Respir Crit Care Med. 2021 Jul 15;204(2):197-208. doi: 10.1164/rccm.202008-3093OC.
8
The Molecular Floodgates of Stress-Induced Senescence Reveal Translation, Signalling and Protein Activity Central to the Post-Mortem Proteome.应激诱导衰老的分子闸门揭示了翻译、信号转导和蛋白质活性是死后蛋白质组的核心。
Int J Mol Sci. 2020 Sep 3;21(17):6422. doi: 10.3390/ijms21176422.
9
Effect of different anaesthetic techniques on gene expression profiles in patients who underwent hip arthroplasty.不同麻醉技术对髋关节置换术患者基因表达谱的影响。
PLoS One. 2019 Jul 25;14(7):e0219113. doi: 10.1371/journal.pone.0219113. eCollection 2019.
10
Long Noncoding RNA Analyses for Osteoporosis Risk in Caucasian Women.长链非编码 RNA 分析在高加索女性骨质疏松症风险中的作用。
Calcif Tissue Int. 2019 Aug;105(2):183-192. doi: 10.1007/s00223-019-00555-8. Epub 2019 May 9.